The platform uses AI and machine learning to identify risk factors for heart attacks

Interview with Steven Loeb and Bambi Francisco Jim Min, founder and CEO of Cleerly, a company that uses artificial intelligence to identify the characteristics of plaques that can cause heart attacks. The platform includes a data visualization platform to improve understanding of heart disease, patient-centered educational solutions, and automated data curation. It is also capable of delivering coronary results in as little as an hour.

Cleerly was founded in 2017 and has $ 54 million

For these digital health podcasts, our goal is to understand these three overarching questions as well: How do we empower consumers? Are we creating a productivity that also enables us to reduce overall economic costs? How is this advancement changing the role of the doctor?

Highlights from the interview:

  • Min spent 15 years at Weill Cornell Medical College and New York-Presbyterian Hospital, where he worked on three things that formed the basis of Cleerly: a cardiovascular disease prevention program; Computer vision and image processing; and clinical studies to understand how disease phenotype affects patient outcome.
  • Cleerly uses a coronary CT angiogram, which is the only non-invasive tool that allows whole heart characterization and quantification of all the different types of plaque buildup. The company takes the angiogram and extracts the CT to the cloud, using machine learning algorithms to analyze the image in just minutes.
  • Even clinicians with no background in imaging can really ingest Cleery’s data. The company visualizes it in a way that they can work to, so that it can assist them in better treating and diagnosing their patients.
  • There are 40% more deaths from cardiovascular disease than from all cancers combined, and there were twice as many cardiovascular deaths as deaths from COVID-19 in the past year. Worldwide, an individual dies of cardiovascular disease every 1.7 seconds. This is partly because people are only screened if they have had symptoms such as chest pain, which is a late stage of the disease.
  • Five years ago there were only two or three drugs that could be used to treat people to keep atherosclerosis and heart attacks from getting worse; In the past four years, the FDA has approved more than 20 different drugs for the prevention of coronary artery disease. The problem is no longer treatment, it is that people are not easily identified. To make the biggest dent, you need to locate people with a disease and provide them with proper treatment early on, before catastrophic events occur.
  • Once plaque has built up, it’s difficult to remove. Medications, a healthy diet, and exercise take plaques and convert them to reduce the risk. Cleerly’s technology enables these phenotypes to be quantified and characterized so that they can be used as an integrated individual metric. This allows doctors to identify a patient’s risk factors and determine if they have more plaque growing.
  • In the clinical studies Cleerly conducted prior to founding the company, it was found that darker, lower density, non-calcified plaques caused a higher risk of heart attack. The darker the plaques and the less calcified they were, the more dangerous they are. Because they become lighter and more calcified over time, these plaques are associated with a lower risk of future heart attacks. This gives doctors a single metric that they can track to track therapy success.
  • Cleerly has partnered with hospitals and integrated health care networks to identify very high risk patients who have been overlooked. There are hundreds of clinical conditions that have been shown to increase the risk of heart disease and heart attacks, but these people are not seen on a daily basis and are not included in the cardiac risk calculator. Cleerly works with its hospital partners to find and evaluate these individuals and provide them with early screening.
  • Cleerly has eight large, multi-center clinical studies underway, some of which are focused on the solution’s diagnostic accuracy and performance. The company completed half of these diagnostic performance studies and the Cleerly platform was over 99% accurate.

This podcast is sponsored by BetterHelp and VatorNews listeners get a 10% discount for the first month at BetterHelp.com/Vator. This podcast is also provided by Octave, your mental health and emotional wellbeing partner. Learn more at FindOctave.com. Also thanks to NeuroFlow, which works with hundreds of health organizations to provide world-class technology and services for the effective integration of behavioral health.

Subscribe to our podcasts to receive our interviews and shows as soon as they are released!

LEAVE A REPLY

Please enter your comment!
Please enter your name here